EUVIMEDEUVIMED entdecken
Leserbrief

Escalated Infliximab Dosing in Hidradenitis Suppurativa: A National Survey of Expert Practice

Adarsh Shidhaye iD, Nicole Edmonds iD, Gabrielle Schwartzman iD, Lindsey Buscemi iD, R Hal Flowers iD

International Journal of Dermatology · 07.08.2026

DOI: 10.1111/ijd.70625 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Journal of Dermatology, online erschienen am 07.08.2026. Verfasst von Adarsh Shidhaye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Medicine, NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA.
  • Department of Dermatology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

ORCID-Profile: Adarsh Shidhaye, Nicole Edmonds, Gabrielle Schwartzman, Lindsey Buscemi, R Hal Flowers

Zitieren

APA

Shidhaye, A., Edmonds, N., Schwartzman, G., Buscemi, L., & Flowers, R. H. (2026). Escalated Infliximab Dosing in Hidradenitis Suppurativa: A National Survey of Expert Practice. International Journal of Dermatology. https://doi.org/10.1111/ijd.70625

Vancouver

Shidhaye A, Edmonds N, Schwartzman G, Buscemi L, Flowers RH. Escalated Infliximab Dosing in Hidradenitis Suppurativa: A National Survey of Expert Practice. International Journal of Dermatology. 2026. doi:10.1111/ijd.70625

BibTeX
@article{Shidhaye2026,
  author = {Shidhaye, Adarsh and Edmonds, Nicole and Schwartzman, Gabrielle and Buscemi, Lindsey and Flowers, R Hal},
  title = {Escalated Infliximab Dosing in Hidradenitis Suppurativa: A National Survey of Expert Practice},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70625}
}
Kostenlos starten →